



ASCELIA  
PHARMA

## Invitation to Exercise Warrants Series TO1 in Ascelia Pharma AB

This information brochure shall be regarded as marketing material and does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Ascelia Pharma AB ("Ascelia Pharma" or the "Company"). The information brochure is not and shall not be deemed to constitute a prospectus under applicable laws and regulations. The invitation to the persons concerned to subscribe for units consisting of ordinary shares and warrants in Ascelia Pharma has only been made through the prospectus published by Ascelia Pharma on 16 August 2024. Readers are requested to read the prospectus for a description of the risks associated with an investment in the Company. This information brochure may not be announced, published or distributed, directly or indirectly, in or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction where such action is wholly or partly subject to legal restrictions.

**Dear warrant holder,**

I hereby invite you to exercise your warrants of series TO 1.

We are excited about our continued progress for Orvigance, including our most recent milestone obtaining feedback from the FDA confirming our finalization of the NDA for submission mid-2025 as planned. We are also progressing our partnership discussions for the commercialization of Orvigance and look forward realizing the potential of Orvigance and provide better access to diagnosis and care for cancer patients with impaired kidney function.

We were pleased to see the fully subscribed Rights Issue in 2024, and we hope to see the same support during the upcoming exercise period for our warrants series TO 1. Financing from the warrants series TO 1 will strengthen our financial position and support successfully meeting our key milestones ahead including NDA submission and Orvigance partnering.

On behalf of the entire Ascelia team, I'd like to thank you for supporting the continued development and growth of Ascelia Pharma towards our mission to improve the lives of people living with rare cancer by providing better treatment options.

***Magnus Corfitzen, CEO***

---

**About Ascelia Pharma**

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orvigance® and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit [www.ascelia.com](http://www.ascelia.com).

## How to exercise your subscription warrants

### Terms

One (1) warrants series TO 1 entitles the holder to subscribe for one (1) new ordinary share in the Company.

### Exercise price

SEK 2.15 per new share. The exercise price has been determined in accordance with the terms and conditions for the warrants series TO 1.

### Exercise period

From April 1, 2025, up to and including April 15, 2025.

### Last day of trading

Holders who do not wish to exercise their subscription warrants may sell them up to and including April 11, 2025.

### Payment

Payment is made in conjunction with subscription of new shares.

## How warrants are exercised

### Nominee-registered warrants (Custody account)

If you hold TO 1 warrants in a custody account, investment savings account (ISK) account or capital insurance account, you must exercise the warrants in accordance with the instructions provided by your nominee regarding subscription and payment. Contact your nominee well in advance of April 15, as different nominees have different processing times.

### Direct-registered warrants (Securities account)

If you hold TO 1 on securities account, you must exercise the warrants by completing and submitting the attached subscription form. The issuing agent Aqurat Fondkommision must receive the subscription form and payment no later than April 15, 2025. The subscription form is available at [www.ascelia.com](http://www.ascelia.com) and [www.aqurat.se](http://www.aqurat.se).

*If you are unsure whether your warrants are nominee-registered or directly-registered, please contact the securities institution where your holdings are kept.*

## Trading in warrants

If you do not wish to exercise your warrants, you have the option to sell them on the Nasdaq Stockholm. The warrants will be traded up to and including April 11, 2025 under the short name ACE TO 1 and with ISIN SE0022725438. Please note that warrants that are not exercised for subscription of ordinary shares by 15 April 2025, at the latest, or sold no later than 11 April 2025, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new ordinary shares or sell the warrants. For more information about the exercise of the warrants series TO 1, please visit [www.aqurat.se](http://www.aqurat.se).

ASCELIA  
PHARMA